Literature DB >> 9854274

Outcome of the depressed elderly living in the community in Liverpool: a 5-year follow-up.

V K Sharma1, J R Copeland, M E Dewey, D Lowe, I Davidson.   

Abstract

BACKGROUND: Comparatively little is known about the long-term natural history of depressive disorders in the elderly living in the community. This is a follow-up of a subsample of the Continuing Health in the Community study random sample of the elderly population living in Liverpool.
METHODS: The investigators followed up 120 cases of depression identified by a semi-structured interview schedule (GMS) for a period of 5 years. A similar number of other subjects defined as subcases of depression, other cases of mental illness and a random selection of non-cases were also included.
RESULTS: The 5-year outcome for the cases of depression was worse than the outcome of the non-cases (relative mortality risk of 2.1, 95% confidence interval 1.1 to 3.9). Thirty-four per cent of the cases of depression died and 28% had dropped out during the follow-up. Of the 46 cases of depression who had a complete follow-up, 22% recovered from their symptoms, 30% were found to be AGECAT cases at one of the three follow-up waves, 24% were AGECAT cases at two of the three follow-up waves and the remaining 24% were AGECAT cases at each follow-up wave. Fifteen per cent of the surviving cases of depression were organic cases at the follow-up. Their anxiety comorbid state and depression score were identified as predictors of poor outcome.
CONCLUSION: The findings of this study indicate that depressive disorders (most of which were untreated) found in the elderly community have a poor prognosis.

Entities:  

Mesh:

Year:  1998        PMID: 9854274     DOI: 10.1017/s0033291798007521

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  8 in total

1.  Depression and incident Alzheimer disease: the impact of disease severity.

Authors:  Patricia Gracia-García; Concepción de-la-Cámara; Javier Santabárbara; Raúl Lopez-Anton; Miguel Angel Quintanilla; Tirso Ventura; Guillermo Marcos; Antonio Campayo; Pedro Saz; Constantine Lyketsos; Antonio Lobo
Journal:  Am J Geriatr Psychiatry       Date:  2013-06-20       Impact factor: 4.105

Review 2.  Use of antidepressants in late-life depression.

Authors:  Tarek K Rajji; Benoit H Mulsant; Francis E Lotrich; Cynthia Lokker; Charles F Reynolds
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

3.  Verbal learning and memory in older adults with minor and major depression.

Authors:  Raquelle I Mesholam-Gately; Anthony J Giuliano; Eric A Zillmer; Lamia P Barakat; Anand Kumar; Ruben C Gur; Lisa M McAndrew; Warren B Bilker; Virginia Elderkin-Thompson; Paul J Moberg
Journal:  Arch Clin Neuropsychol       Date:  2011-12-21       Impact factor: 2.813

4.  Depression, cardiovascular disease, diabetes, and two-year mortality among older, primary-care patients.

Authors:  Joseph J Gallo; Hillary R Bogner; Knashawn H Morales; Edward P Post; Thomas Ten Have; Martha L Bruce
Journal:  Am J Geriatr Psychiatry       Date:  2005-09       Impact factor: 4.105

Review 5.  Increased mortality in depressive disorders: a review.

Authors:  Pim Cuijpers; Robert A Schoevers
Journal:  Curr Psychiatry Rep       Date:  2004-12       Impact factor: 5.285

6.  Heterogeneity in the three-year course of major depression among older adults.

Authors:  Celia F Hybels; Carl F Pieper; Dan G Blazer; David C Steffens
Journal:  Int J Geriatr Psychiatry       Date:  2015-11-11       Impact factor: 3.485

7.  Higher burden of depression among older women: the effect of onset, persistence, and mortality over time.

Authors:  Lisa C Barry; Heather G Allore; Zhenchao Guo; Martha L Bruce; Thomas M Gill
Journal:  Arch Gen Psychiatry       Date:  2008-02

8.  The B-VITAGE trial: a randomized trial of homocysteine lowering treatment of depression in later life.

Authors:  Andrew H Ford; Leon Flicker; Kieran McCaul; Frank van Bockxmeer; Sarah Hegarty; Varsha Hirani; Stephen Fenner; Osvaldo P Almeida
Journal:  Trials       Date:  2010-01-25       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.